Meta launches AI algorithm personalization feature for Threads
The feature, called “Dear Algo,” lets Threads users personalize what content they see by publicly posting an AI prompt.
Investor Einhorn said he bought Peloton again on this latest dip. Here’s what else he’s buying
The Greenlight Capital founder said investors have overreacted to Peloton’s latest earnings results, and named a few other stocks that look attractive from here.
Stocks making the biggest moves midday: Acadia Healthcare, Vertiv, Moderna, Unity Software, Generac & more
These are the stocks posting the largest moves in midday trading.
David Einhorn says the Fed will cut ‘substantially more’ than two times. So he’s betting big on gold
Greenlight Capital’s David Einhorn anticipates the Federal Reserve will issue more interest rate cuts than what’s being anticipated.
Here are the five key takeaways from the January jobs report
The January nonfarm payrolls report beat Wall Street expectations in both job creation and the unemployment rate.
Prediction markets head into basketball season on a high from Super Bowl
Prediction markets let users buy event contracts for a wide swath of financial, weather and pop culture events, but sports have been driving profits.
Wealth stocks dropped on fears AI is coming for them next. Morgan Stanley and others say buy the dip
The sell-off in financial services stocks on new fears over artificial intelligence has created a buying opportunity, according to several Wall Street analysts.
Watch: AG Bondi touts Dow records as furious Dems grill her over Epstein and Trump
Bondi’s sworn testimony came after Rep. Jerrold Nadler, D-N.Y., slammed the DOJ for so far failing to indict any Jeffrey Epstein co-conspirators.
House to vote on Trump bid for tough voter-ID SAVE Act
The SAVE America Act’s GOP supporters say it would secure elections and prevent fraud. Democrats say it could disenfranchise millions.
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Doustdar said Medicare coverage and the launch of Novo’s new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.